Cargando…
Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8(+ )T cell immunity
Developing new vaccination strategies and optimizing current vaccines through heterologous prime-boost carries the promise of integrating the benefits of different yet synergistic vectors. It has been widely thought that the increased immunity afforded by heterologous prime-boost vaccination is main...
Autores principales: | Bot, Adrian, Qiu, Zhiyong, Wong, Raymond, Obrocea, Mihail, Smith, Kent A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012026/ https://www.ncbi.nlm.nih.gov/pubmed/21144062 http://dx.doi.org/10.1186/1479-5876-8-132 |
Ejemplares similares
-
CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022) -
Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022) -
Cancer vaccines at an inflexion point: what next?
por: Bot, Adrian, et al.
Publicado: (2011) -
Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8(+) T Cell Responses
por: Ring, Sandra S., et al.
Publicado: (2020) -
Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)